We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$701M
AUM Growth
+$112M
Cap. Flow
+$80.1M
Cap. Flow %
11.43%
Top 10 Hldgs %
45.26%
Holding
159
New
30
Increased
40
Reduced
26
Closed
28

Top Buys

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14.1M
2
AGN
Allergan plc
AGN
+$14M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$9M
4
MRK icon
Merck
MRK
+$6.67M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.17M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$16M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.99M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 62.92%
2 Technology 5.67%
3 Communication Services 2.64%
4 Industrials 1.06%
5 Financials 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
26
DELISTED
Immunomedics Inc
IMMU
$6.29M 0.9%
450,000
-100,000
-18% -$997K
PVLA
27
Palvella Therapeutics
PVLA
$1.99B
$5.76M 0.82%
12,500
-1,250
-9% -$534K
EIGR
28
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5.72M 0.82%
17,342
+4,499
+35% +$1.23M
RXDX
29
DELISTED
Ignyta, Inc.
RXDX
$5.67M 0.81%
459,300
+59,300
+15% +$611K
GOOGL icon
30
Alphabet (Google) Class A
GOOGL
$4.36T
$5.62M 0.8%
115,340
+28,420
+33% +$1.35M
V icon
31
Visa
V
$684B
$5.57M 0.8%
52,951
– –
META icon
32
Meta Platforms (Facebook)
META
$1.42T
$5.5M 0.78%
32,167
– –
NBIX icon
33
Neurocrine Biosciences
NBIX
$16.8B
$5.33M 0.76%
87,000
+25,000
+40% +$1.32M
LJPC
34
DELISTED
La Jolla Pharmaceutical Company
LJPC
$5.22M 0.74%
150,000
+25,000
+20% +$804K
AVEO
35
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$5.11M 0.73%
140,000
-80,000
-36% -$2.47M
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$5.08M 0.73%
+145,000
New +$1.97M
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$4.98M 0.71%
405,000
-295,000
-42% -$2.74M
SVRA icon
38
Savara
SVRA
$1.12B
$4.92M 0.7%
526,315
– –
CHTR icon
39
Charter Communications
CHTR
$17.3B
$4.86M 0.69%
13,362
– –
NERV icon
40
Minerva Neurosciences
NERV
$185M
$4.75M 0.68%
78,125
+18,904
+32% +$1.08M
VTRS icon
41
CALL
Viatris
VTRS
$20.4B
$4.71M 0.67%
150,000
+148,500
+9,900% +$5.04M
ASND icon
42
Ascendis Pharma A/S
ASND
$16B
$4.69M 0.67%
129,474
-32,143
-20% -$922K
SPNS
43
DELISTED
Sapiens International
SPNS
$4.65M 0.66%
354,866
+207,560
+141% +$2.43M
TVTX icon
44
Travere Therapeutics
TVTX
$5.2B
$4.33M 0.62%
174,131
-35,000
-17% -$771K
INSM icon
45
Insmed
INSM
$21.4B
$4.21M 0.6%
+135,000
New +$2.57M
RNAC icon
46
Cartesian Therapeutics
RNAC
$229M
$4.17M 0.6%
7,618
– –
GLD icon
47
SPDR Gold Trust
GLD
$131B
$4.04M 0.58%
+33,190
New +$4.04M
GBT
48
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.94M 0.56%
127,000
-23,000
-15% -$647K
PRTA icon
49
Prothena Corp
PRTA
$425M
$3.89M 0.55%
60,000
+20,000
+50% +$1.23M
MGNX icon
50
MacroGenics
MGNX
$235M
$3.86M 0.55%
208,700
+127,500
+157% +$2.21M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sphera Funds Management held 159 positions worth $701M, up 19% from $589M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $80.1M of net new capital in Q3 2017, opening 30 new positions and adding to 40 existing holdings. Its largest new stake was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Caesarstone, an estimated $3.28M trimmed.

  • Sphera Funds Management's largest Q3 2017 buy was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.
  • Sphera Funds Management added most to Merck in Q3 2017, an estimated $6.67M increase.
  • Sphera Funds Management's biggest Q3 2017 reduction was Caesarstone, cutting an estimated $3.28M.
  • Sphera Funds Management fully exited Novartis in Q3 2017, selling an estimated $16M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $701M portfolio in Q3 2017.
  • Sphera Funds Management opened 30 new positions and closed 28 in Q3 2017.
  • Sphera Funds Management's portfolio value rose 19% quarter-over-quarter to $701M.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.